Adagio Therapeutics Announces Dosing of First Patient in Phase 1 Trial of ADG20, its Lead Monoclonal Antibody Candidate for the Treatment and…

Feb. 16, 2021 12:00 UTC

-ADG20 is uniquely engineered to maximize potency, duration of effect, and ease of use in the community setting, and has shown outstanding manufacturability to meet global demand-

-ADG20 binds to a highly conserved region of the spike protein not targeted by other antibodies, enabling potent neutralization to all known SARS-CoV-2 variants and several pre-emergent coronavirus threats-

WALTHAM, Mass.--(BUSINESS WIRE)-- Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced the initiation of a Phase 1 clinical trial evaluating its lead monoclonal antibody product candidate, ADG20. The Phase 1 trial will be conducted in the United States and will evaluate the safety, tolerability and pharmacokinetics of ADG20, including serum SARS-CoV-2 neutralizing antibody levels, in healthy participants. Once adequate safety data are evaluated, Adagio plans to advance ADG20 into global pivotal trials for the treatment and prevention of COVID-19, including in countries with high rates of resistant variants.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210216005243/en/

Tillman Gerngross, Co-Founder and CEO, Adagio Therapeutics, Inc. (Photo: Business Wire)

We are in the unique position of having a monoclonal antibody that binds to and protects against common circulating SARS-CoV-2 variants as well as SARS-related viruses with pandemic potential. This broadly neutralizing activity was intentionally designed into ADG20, as we anticipated the continued emergence of resistance mutations, and we took deliberate steps to engineer ADG20 to maximize its potential to avoid viral escape. This design feature also enables ADG20 to target and neutralize coronaviruses that may emerge in the future, said Tillman Gerngross, Chief Executive Officer of Adagio. Were very proud of the impressive work the team at Adagio has done, rapidly moving from lead identification and manufacturing into clinical trials within eight months.

This Phase 1 study is the first step in the clinical development of ADG20, our broadly-neutralizing antibody for coronavirus threats, and we expect it to provide key information regarding safety, pharmacokinetics and serum SARS-CoV-2 neutralizing antibody levels, said Lynn Connolly, Chief Medical Officer of Adagio. We plan to evaluate intramuscular administration of ADG20, which could be a critical differentiator for patients and providers, allowing for administration in the community setting for both prevention and treatment of COVID-19. We will be evaluating ADG20 across multiple clinical settings on a global basis from pre- and post-exposure prophylaxis to treatment. We are currently focused on outpatient populations, including an emphasis on addressing unmet needs in vulnerable groups such as the immune compromised and children.

In this Phase 1, randomized, double-blind, single ascending-dose study, healthy adult participants will either receive an intramuscular or intravenous dose of ADG20 or placebo. The primary endpoint of the study is safety and tolerability, while secondary endpoints include evaluations of pharmacokinetics and immunogenicity. The study will also explore the serum neutralizing activity of ADG20 ex vivo against SARS-CoV-2.

In closing, Gerngross notes, We believe ADG20 is poised to address the endemic nature of SARS-CoV-2 as well as the pandemic potential of future coronaviruses. We are excited to initiate clinical trials and potentially commercialize a differentiated antibody whose combined attributes address key limitations of other antibody programs and have the potential to address the significant unmet need that remains in the treatment and prevention of COVID-19.

About Adagio Therapeutics

Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional pre-emergent coronaviruses. Our candidates are optimized using Adimabs industry-leading antibody engineering capabilities and are designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection (via half-life extension), manufacturability, tolerability, and affordability. Our portfolio of SARS-CoV-2 antibodies includes multiple, non-competing antibodies with distinct binding epitopes. Pre-clinical data show that our lead antibody ADG20 matches or exceeds the potency and coverage of other clinical SARS-CoV-2 antibody programs. We plan to advance ADG20 aggressively through global clinical trials for both the prevention and treatment of symptomatic COVID-19 and anticipate data from both prevention and treatment clinical trials in 2021. Adagio has secured manufacturing capacity for the production of ADG20 with third party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information: http://www.adagiotx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005243/en/

See the article here:

Adagio Therapeutics Announces Dosing of First Patient in Phase 1 Trial of ADG20, its Lead Monoclonal Antibody Candidate for the Treatment and...

Crypto market report: Bitcoin, Ethereum, Litecoin & Co .: How the crypto prices develop on Saturday | message – The Times Hub

The Bitcoin price fell on Saturday. At noon, Bitcoin fell to $ 46,887.78 after trading at $ 47,586.24 the day before.

Bitcoin Cash price fell to $ 558.30 after trading at $ 579.65 the previous day.

display

Do you want to invest in Bitcoin? We explain the possibilities to youHere you can easily buy and sell Bitcoin

Ethereum is in the red at $ 1,797.30.

The previous evening, the digital currency was still at $ 1,846.07.

The price of the digital currency Litecoin rose to 198.73 US dollars on Saturday.

The day before, the rate of the digital currency was put at 197.45 US dollars.

The ripple is worth $ 0.5817 on Saturday.

The Ripple price fell compared to the previous day when it was still at $ 0.6138.

The Cardano course has fallen compared to the previous day. A Cardano is currently worth $ 0.8810.

The price was yesterday at $ 0.9254.

The course of the digital currency Monero is quoted today at 214.78 US dollars in the plus.

The previous day the price was $ 201.19.

The IOTA course is stronger than the day before. One IOTA is currently worth $ 1.266. Yesterday the price was still at $ 1.232.

The Verge price runs sideways at 0.0255 US dollars compared to the previous days level.

The Stellar exchange rate rose to $ 0.5423 compared to the previous day.

There was still $ 0.5258 on the price board.

The NEM rate trades lighter at $ 0.3870.

The previous day the price was $ 0.3986.

The Dash price rose to $ 207.98.

The day before, the cryptocurrency was worth $ 168.16.

The price of the NEO rose to $ 36.86 today, while the previous day it was trading at $ 37.99.

Finanzen.net editorial team

Image sources: Wit Olszewski / Shutterstock.com

Natasha Kumar has been a reporter on the news desk since 2018. Before that she wrote about young adolescence and family dynamics for Styles and was the legal affairs correspondent for the Metro desk. Before joining The Times Hub, Natasha Kumar worked as a staff writer at the Village Voice and a freelancer for Newsday, The Wall Street Journal, GQ and Mirabella. To get in touch, contact me through my [emailprotected] 1-800-268-7116

More:

Crypto market report: Bitcoin, Ethereum, Litecoin & Co .: How the crypto prices develop on Saturday | message - The Times Hub

Ethereum Posts 450% Gain in 2020, Beats Bitcoin – Finance Magnates

Ethereum, the second-largest cryptocurrency in the world, posted a significant gain in 2020 as the price of ETH increased by more than 450%. Ethereum has performed better than Bitcoin this year.

Ethereum is currently trading around $730, a significant jump from $129 at the start of 2020. On the other hand, the worlds largest cryptocurrency Bitcoin is hovering around $28,000, compared to around $7,200 at the start of this year. BTC posted a nearly 300% gain since the start of 2020.

ETH price is not the only indicator that shows its performance. Grayscale, a leading cryptocurrency asset management firm reported growing interest in ETH-related investment products earlier this year. Michael Sonnenshein, Managing Director at Grayscale Investments, outlined the growing interest of institutional investors in Ethereum.

Jesse Willms on Making The Most Of The eCommerce BoomGo to article >>

Over the course of 2020, we are seeing a new group of investors who are Ethereum-first and in some cases Ethereum-only. Theres a growing conviction around ETH as an asset class. The development of the asset class has continued to solidify itself, he mentioned in an interview.

On the last day of 2020, Ethereum touched the $750 mark, its highest level since March 2018. The price of ETH is still far away from its all-time high of $1380, but the recent price action shows that the worlds second-largest cryptocurrency is set to test new highs in 2021. ETHs recent introduction of Beacon Chain and its network upgrade to make the entire system more efficient attracted several institutional investors to participate in Ethereum 2.0 staking. The current market cap of ETH stands at around $83 billion.

Due to the growing interest of investors in Ethereum 2.0, several cryptocurrency exchanges started offering ETH staking services, including Binance. Finance Magnates earlier reported about the support from cryptocurrency exchange Gemini for the latest upgrade of the ETH network. But, the key driver has been the institutional adoption of the worlds second-largest cryptocurrency. Institutional investors started including ETH in their investment portfolios this year.

See original here:

Ethereum Posts 450% Gain in 2020, Beats Bitcoin - Finance Magnates